About GenomOncology
GenomOncology is a company based in Cleveland (United States) founded in 2012. GenomOncology has raised $6.09 million across 5 funding rounds from investors including TriStar Health Partners and JumpStart Ventures. GenomOncology offers products and services including Precision Oncology Platform, Data Enablement, Pathology Decision Support, Insights & Analytics, and Curation Services. GenomOncology operates in a competitive market with competitors including Denali Therapeutics, MiRagen, Poseida Therapeutics, Juno Therapeutics and Castle Biosciences, among others.
- Headquarter Cleveland, United States
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Genomoncology Llc
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$6.09 M (USD)
in 5 rounds
-
Latest Funding Round
$3.2 M (USD), Series A
Apr 24, 2020
-
Investors
TriStar Health Partners
& 1 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of GenomOncology
GenomOncology offers a comprehensive portfolio of products and services, including Precision Oncology Platform, Data Enablement, Pathology Decision Support, Insights & Analytics, and Curation Services.
Transforms complex data into actionable insights for cancer care.
Harnesses data to enhance operational efficiency in healthcare.
Processes genetic test results for clinical insights.
Analyzes patient data to improve cancer care outcomes.
Provides curated content for precision oncology solutions.
People of GenomOncology
Unlock access to complete
Unlock access to complete
Funding Insights of GenomOncology
GenomOncology has successfully raised a total of $6.09M across 5 strategic funding rounds. The most recent funding activity was a Series A round of $3.2 million completed in April 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in GenomOncology
GenomOncology has secured backing from 2 investors, including venture fund investors. Prominent investors backing the company include TriStar Health Partners and JumpStart Ventures.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Locked | Locked | Locked | |
|
Venture capital funding is provided to tech startups by JumpStart Ventures.
|
Locked | Locked | Locked |
Investor details for GenomOncology
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by GenomOncology
Investment portfolio details for GenomOncology
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - GenomOncology
Detailed financials for GenomOncology
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Genomoncology Comparisons
Peer comparison for GenomOncology
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of GenomOncology
GenomOncology operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Denali Therapeutics, MiRagen, Poseida Therapeutics, Juno Therapeutics and Castle Biosciences, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Neurodegenerative disease therapies are developed for Alzheimer's, ALS, and Parkinson's.
|
|
| Locked | Locked | Locked |
MicroRNA-based therapeutics are developed for treating multiple diseases.
|
|
| Locked | Locked | Locked |
Developer of gene therapies for treating cancer and liver orphan disease by using gene editing technologies
|
|
| Locked | Locked | Locked |
CAR T-cell and T-cell receptor immunotherapies for cancer are developed.
|
|
| Locked | Locked | Locked |
Precision diagnostic and prognostic tests are developed by Castle Biosciences.
|
|
| Locked | Locked | Locked |
Therapeutics for aging diseases are developed by targeting senescent cells.
|
Detailed competitors of GenomOncology
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Genomoncology
Complete news archive for GenomOncology
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about GenomOncology
GenomOncology was founded in 2012.
GenomOncology is headquartered in Cleveland, United States. It is registered at Cleveland, Ohio, United States.
GenomOncology is a funded company, having raised a total of $6.09M across 5 funding rounds to date.
GenomOncology is a healthcare technology company enabling precision medicine by transforming genomic data into actionable information. It has developed a proprietary technology platform to streamline the use of next-generation sequencing in medicine and research. Precision Medicine Portfolio is a suite of products and services that addresses for precision medicine in molecular pathology and medical genetics, particularly in the field of oncology and other hereditary diseases. This portfolio supports test validation and production, clinical decision support, and analytics for both monitoring and discovery. Its other products include the GO Validation Toolkit, the GO Clinical Workbench, and GenomAnalytics. It also offers scientific services like test validation, customization, integration, and research.
GenomOncology's top competitors include Juno Therapeutics, Poseida Therapeutics and Denali Therapeutics.
GenomOncology offers Precision Oncology Platform, Data Enablement, Pathology Decision Support, Insights & Analytics, and Curation Services.
GenomOncology has 2 investors. Key investors include TriStar Health Partners, and JumpStart Ventures.